Friedlander, Michael <br/><br/>
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.  [electronic resource] 

 -  British journal of cancer  10 2018 
 - 1075-1085 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/s41416-018-0271-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Capsules<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Maintenance Chemotherapy<br/>Middle Aged<br/>Mutation<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Platinum--administration & dosage<br/>Treatment Outcome<br/>Young Adult